View ValuationEOM Pharmaceuticals Holdings 将来の成長Future 基準チェック /06現在、 EOM Pharmaceuticals Holdingsの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Biotechs 収益成長25.2%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Jan 07EOM Pharmaceutical Holdings, Inc. Reports Promising Preclinical Results and Provides an Update on EOM613 and EOM147EOM Pharmaceutical Holdings, Inc. provided an update on its preclinical programs in 2025 and its planned clinical activities in 2026 for its two lead product candidates EOM613 and EOM147. In 2025, the company completed IND-enabling toxicological and dosing preclinical animal studies for EOM613 with favorable results. In addition, no adverse effects were seen in tissue upon histopathological testing. Based on these data, combined with previously reported promising results of Phase I/IIa 2023 human clinical trial in hospitalized COVID-19 patients with cytokine-driven respiratory inflammation in Brazil, the company planning an initial Phase II exploratory clinical trial in patients with Crohn's disease. This trial is designed to include 15-20 patients and will be conducted at clinical sites in New Brunswick and Lakewood, NJ, under Principal Investigator Arkady Broder, MD, Director of Gastroenterology at the St. Peter's Healthcare System. The trial will enroll subjects with moderate to severe Crohn's disease who have failed or could not tolerate at least one conventional therapy. EOM anticipates initiating the trial in the first quarter 2026 to test for signs of clinical remission and endoscopic remission with EOM613 treatment and to measure biomarkers such as C-reactive protein, calprotectin and pro-inflammatory serum cytokines. In addition, based on these preclinical results, EOM plans to reactivate an Investigational New Drug (IND) application for the treatment of cachectic cancer patients at the FDA's Office of Oncologic Diseases (OOD) with a view to conducting an open-label Phase II trial with Stage 4 cancer patients. The trial's Principal Investigator is Azriel Hirschfeld, MD, at Hirschfeld Oncology in Brooklyn, NY, an expert in the treatment of gastrointestinal cancer patients with advanced disease who typically progress to a cachectic condition. In previous clinical trials in AIDS, cancer cachexia and COVID-19 patients, EOM613 treatment was well-tolerated, even in very sick patients. A broad-spectrum immune regulating agent that regulates pro-and anti-inflammatory cytokines in patients without the risk of severe side effects associated with the use of antibody or corticosteroid drugs could be beneficial in the treatment of Crohn's disease and ulcerative colitis.お知らせ • Sep 08EOM Pharmaceutical Holdings Announces Topline Results of Its Covid-19 Clinical Trial of Eom613 in BrazilEOM Pharmaceutical Holdings, Inc. announced the results of its completed clinical trial in hospitalized COVID-19 patients with severe symptoms treated with its investigational immune-regulating drug product EOM613. The trial was conducted in Brazil. This exploratory Phase 1/2a clinical trial (NCT05212532), designated RESCUE, was a proof-of-concept, open-label study evaluating the safety, tolerability, and preliminary efficacy measures, such as the effects on serum cytokines, when EOM613 was added to the standard-of-care therapy. The trial included two cohorts of patients hospitalized for COVID-19: one cohort was in the intensive care unit (ICU) and the other cohort was not (non-ICU). The study was conducted at four different medical centers in the Brazilian states of Sao Paolo and Goaia. The trial was originally designed to enroll a total of 40 patients – 20 in each cohort. The trial was redesigned, however, due to challenges in patient enrollment during the COVID-19 pandemic as a result of Brazil's successful vaccination program which led to a reduction in eligible hospitalized patients. The redesigned trial enrolled a total of 23 patients eligible for evaluation. The study's Principal Investigator was Florentino Cardoso Filho, MD, at the Casa de Saude Hospital in Campinas, Sao Paolo, and former President of the Brazilian Medical Association.お知らせ • Aug 03EOM Pharmaceuticals Holdings, Inc. has withdrawn its IPO in the amount of $15 million.EOM Pharmaceuticals Holdings, Inc. has withdrawn its IPO in the amount of $15 million. Security Name: Common Stock Security Type: Common Stockお知らせ • Jun 25ImmunoCellular Therapeutics, Ltd. has filed an IPO in the amount of $25 million.ImmunoCellular Therapeutics, Ltd. has filed an IPO in the amount of $25 million. Security Name: Common Stock Security Type: Common Stock このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、EOM Pharmaceuticals Holdings は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測OTCPK:IMUC - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数9/30/2022N/A-5-3-3N/A3/31/2022N/A-5-2-2N/A12/31/2021N/A-5-2-2N/A9/30/2021N/A-4-3-3N/Aアナリストによる今後の成長予測収入対貯蓄率: IMUCの予測収益成長が 貯蓄率 ( 3.5% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: IMUCの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: IMUCの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: IMUCの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: IMUCの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: IMUCの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/24 05:05終値2026/05/22 00:00収益2022/09/30年間収益2021/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋EOM Pharmaceuticals Holdings, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Jan 07EOM Pharmaceutical Holdings, Inc. Reports Promising Preclinical Results and Provides an Update on EOM613 and EOM147EOM Pharmaceutical Holdings, Inc. provided an update on its preclinical programs in 2025 and its planned clinical activities in 2026 for its two lead product candidates EOM613 and EOM147. In 2025, the company completed IND-enabling toxicological and dosing preclinical animal studies for EOM613 with favorable results. In addition, no adverse effects were seen in tissue upon histopathological testing. Based on these data, combined with previously reported promising results of Phase I/IIa 2023 human clinical trial in hospitalized COVID-19 patients with cytokine-driven respiratory inflammation in Brazil, the company planning an initial Phase II exploratory clinical trial in patients with Crohn's disease. This trial is designed to include 15-20 patients and will be conducted at clinical sites in New Brunswick and Lakewood, NJ, under Principal Investigator Arkady Broder, MD, Director of Gastroenterology at the St. Peter's Healthcare System. The trial will enroll subjects with moderate to severe Crohn's disease who have failed or could not tolerate at least one conventional therapy. EOM anticipates initiating the trial in the first quarter 2026 to test for signs of clinical remission and endoscopic remission with EOM613 treatment and to measure biomarkers such as C-reactive protein, calprotectin and pro-inflammatory serum cytokines. In addition, based on these preclinical results, EOM plans to reactivate an Investigational New Drug (IND) application for the treatment of cachectic cancer patients at the FDA's Office of Oncologic Diseases (OOD) with a view to conducting an open-label Phase II trial with Stage 4 cancer patients. The trial's Principal Investigator is Azriel Hirschfeld, MD, at Hirschfeld Oncology in Brooklyn, NY, an expert in the treatment of gastrointestinal cancer patients with advanced disease who typically progress to a cachectic condition. In previous clinical trials in AIDS, cancer cachexia and COVID-19 patients, EOM613 treatment was well-tolerated, even in very sick patients. A broad-spectrum immune regulating agent that regulates pro-and anti-inflammatory cytokines in patients without the risk of severe side effects associated with the use of antibody or corticosteroid drugs could be beneficial in the treatment of Crohn's disease and ulcerative colitis.
お知らせ • Sep 08EOM Pharmaceutical Holdings Announces Topline Results of Its Covid-19 Clinical Trial of Eom613 in BrazilEOM Pharmaceutical Holdings, Inc. announced the results of its completed clinical trial in hospitalized COVID-19 patients with severe symptoms treated with its investigational immune-regulating drug product EOM613. The trial was conducted in Brazil. This exploratory Phase 1/2a clinical trial (NCT05212532), designated RESCUE, was a proof-of-concept, open-label study evaluating the safety, tolerability, and preliminary efficacy measures, such as the effects on serum cytokines, when EOM613 was added to the standard-of-care therapy. The trial included two cohorts of patients hospitalized for COVID-19: one cohort was in the intensive care unit (ICU) and the other cohort was not (non-ICU). The study was conducted at four different medical centers in the Brazilian states of Sao Paolo and Goaia. The trial was originally designed to enroll a total of 40 patients – 20 in each cohort. The trial was redesigned, however, due to challenges in patient enrollment during the COVID-19 pandemic as a result of Brazil's successful vaccination program which led to a reduction in eligible hospitalized patients. The redesigned trial enrolled a total of 23 patients eligible for evaluation. The study's Principal Investigator was Florentino Cardoso Filho, MD, at the Casa de Saude Hospital in Campinas, Sao Paolo, and former President of the Brazilian Medical Association.
お知らせ • Aug 03EOM Pharmaceuticals Holdings, Inc. has withdrawn its IPO in the amount of $15 million.EOM Pharmaceuticals Holdings, Inc. has withdrawn its IPO in the amount of $15 million. Security Name: Common Stock Security Type: Common Stock
お知らせ • Jun 25ImmunoCellular Therapeutics, Ltd. has filed an IPO in the amount of $25 million.ImmunoCellular Therapeutics, Ltd. has filed an IPO in the amount of $25 million. Security Name: Common Stock Security Type: Common Stock